Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022
myvac
TG4001
: expanded randomized Phase II trial to start in HPV-positive anogenital cancers, based on encouraging Phase Ib/II data
BT-001
Invir.IO platform following the partial sale of the stake in Tasly BioPharmaceuticals in 2020
Conference call in English scheduled today at 6:00 p.m. CET Video conference in French on March 10 at 10:00 a.m. CET (details at the end of the release)
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2020 and provides an update on its product pipeline.